Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal

19
5
Favorite

Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal

Reuters2021-05-03

(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR & Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.

The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.

Investors including Fidelity Management & Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.

After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.

SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（5）

LemonTrader
·2021-05-04
Hi
Reply
Like
Report
ONGEE
·2021-05-03
Tq
Reply
Like
Report
belle111
·2021-05-03
Wow
Reply
Like
Report
LBear
·2021-05-03
Good... pls like and respond to my comment
Reply
Like
Report
Gab_Boey
·2021-05-03
Latest
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1106857820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-05-03 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106857820","market":"us","top_or_hot":-1,"title":"Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal","media":"Reuters","content":"<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Roivant Sciences to go public via $7.3 billion SPAC deal\n</h2>\n\n<h4 class=\"meta\">\n\n2021-05-03 19:29 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR & Co dealmaker Jim Momtazee, in a deal ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":null,"article_id":"1106857820","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106857820","pubTimestamp":1620041381,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"生物技术公司Roivant Sciences将通过73亿美元SPAC交易上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MAAC":0.9},"content_text":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR & Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.Investors including Fidelity Management & Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":106922314,"gmtCreate":1620085348038,"gmtModify":1704338305532,"author":{"id":"3555298390772050","authorId":"3555298390772050","authorIdStr":"3555298390772050","name":"LemonTrader","avatar":"https://static.tigerbbs.com/385f6b70b296a1f1e75b0fd45e9e3c84","vip":1,"hat":"https://static.tigerbbs.com/6444b4970948c1077534c593eccd6d16","crmLevel":5,"crmLevelSwitch":0,"idStr":"3555298390772050"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106922314","repostId":1106857820,"repostType":4,"repost":{"id":"1106857820","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1620041381,"share":"https://ttm.financial/m/news/1106857820?lang=&edition=fundamental","pubTime":"2021-05-03 19:29","market":"us","language":"en","title":"Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1106857820","media":"Reuters","summary":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm","content":"<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Roivant Sciences to go public via $7.3 billion SPAC deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-03 19:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106857820","content_text":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR & Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.Investors including Fidelity Management & Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108571786,"gmtCreate":1620046062845,"gmtModify":1704337803312,"author":{"id":"3581033339387457","authorId":"3581033339387457","authorIdStr":"3581033339387457","name":"ONGEE","avatar":"https://static.tigerbbs.com/8f2e25f5f62eceb73eee0c3248ff25a2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581033339387457"},"htmlText":"Tq","listText":"Tq","text":"Tq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108571786","repostId":1106857820,"repostType":4,"repost":{"id":"1106857820","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1620041381,"share":"https://ttm.financial/m/news/1106857820?lang=&edition=fundamental","pubTime":"2021-05-03 19:29","market":"us","language":"en","title":"Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1106857820","media":"Reuters","summary":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm","content":"<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Roivant Sciences to go public via $7.3 billion SPAC deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-03 19:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106857820","content_text":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR & Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.Investors including Fidelity Management & Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108561796,"gmtCreate":1620042508015,"gmtModify":1704337746870,"author":{"id":"3576012921296307","authorId":"3576012921296307","authorIdStr":"3576012921296307","name":"belle111","avatar":"https://static.tigerbbs.com/6f46e52365860eac5a81ef82845a2f73","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576012921296307"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108561796","repostId":1106857820,"repostType":4,"repost":{"id":"1106857820","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1620041381,"share":"https://ttm.financial/m/news/1106857820?lang=&edition=fundamental","pubTime":"2021-05-03 19:29","market":"us","language":"en","title":"Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1106857820","media":"Reuters","summary":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm","content":"<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Roivant Sciences to go public via $7.3 billion SPAC deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-03 19:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106857820","content_text":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR & Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.Investors including Fidelity Management & Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108569193,"gmtCreate":1620042291712,"gmtModify":1704337742953,"author":{"id":"3581589791636658","authorId":"3581589791636658","authorIdStr":"3581589791636658","name":"LBear","avatar":"https://static.tigerbbs.com/d72234592d914855ae6961fe2dd96980","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581589791636658"},"htmlText":"Good... pls like and respond to my comment","listText":"Good... pls like and respond to my comment","text":"Good... pls like and respond to my comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108569193","repostId":1106857820,"repostType":4,"repost":{"id":"1106857820","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1620041381,"share":"https://ttm.financial/m/news/1106857820?lang=&edition=fundamental","pubTime":"2021-05-03 19:29","market":"us","language":"en","title":"Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1106857820","media":"Reuters","summary":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm","content":"<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Roivant Sciences to go public via $7.3 billion SPAC deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-03 19:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106857820","content_text":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR & Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.Investors including Fidelity Management & Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":108560053,"gmtCreate":1620042152972,"gmtModify":1704337741156,"author":{"id":"3579833810423165","authorId":"3579833810423165","authorIdStr":"3579833810423165","name":"Gab_Boey","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579833810423165"},"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108560053","repostId":1106857820,"repostType":4,"repost":{"id":"1106857820","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1620041381,"share":"https://ttm.financial/m/news/1106857820?lang=&edition=fundamental","pubTime":"2021-05-03 19:29","market":"us","language":"en","title":"Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1106857820","media":"Reuters","summary":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm","content":"<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Roivant Sciences to go public via $7.3 billion SPAC deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-03 19:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106857820","content_text":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR & Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.Investors including Fidelity Management & Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":19,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}